Table 1.
Demographic and clinical charactristics of SMART-AV participants with SAI QRST tertiles.
| Baseline Characteristic | All Patients N=234 |
Tertile 1 (6.8–24.3) N=79 |
Tertile 2 (24.3–67.8) N=77 |
Tertile 3 (67.9–986.3) N=78 |
ANOVA P-value |
|---|---|---|---|---|---|
| Age(years), Mean±SD | 67 ± 10 | 67 ± 10 | 66 ± 10 | 66 ± 11 | 0.83 |
| Female, N(%) | 71 (30.3%) | 27 (34.2%) | 23 (29.9%) | 21 (26.9%) | 0.62 |
| White, N(%) | 181 (79.7%) | 65 (82.3%) | 61 (81.3%) | 55 (75.3%) | 0.55 |
| BMI (kg/m2), Mean±SD | 30.2 ± 6.3 | 29.9 ± 6.5 | 30.3 ± 6.5 | 30.3 ± 5.9 | 0.92 |
| NYHA Class I, N(%) | 1 (0.4%) | 1 (1.3%) | 0 (0.0%) | 0 (0.0%) | 0.055 |
| NYHA Class II, N(%) | 9 (3.9%) | 7 (9.0%) | 1 (1.3%) | 1 (1.3%) | |
| NYHA Class III, N(%) | 215 (92.3%) | 69 (88.5%) | 72 (93.5%) | 74 (94.9%) | |
| NYHA Class IV, N(%) | 8 (3.4%) | 1 (1.3%) | 4 (5.2%) | 3 (3.8%) | |
| LBBB, N(%) | 179 (76.5%) | 63 (79.7%) | 55 (71.4%) | 61 (78.2%) | 0.43 |
| Ischemic cardiomyopathy, N(%) | 140 (59.8%) | 47 (59.5%) | 51 (66.2%) | 42 (53.8%) | 0.30 |
| LVEF(%), Mean±SD | 24.7 ± 6.9 | 25.8 ± 6.5 | 24.9 ± 6.9 | 23.5 ± 7.2 | 0.12 |
| LVESV(ml), Mean±SD | 126 ± 66 | 109 ± 51 | 115 ± 55 | 154 ± 80 | < 0.001 |
| QRS(ms), Mean±SD | 152 ± 20 | 147 ± 21 | 150 ± 20 | 160 ± 15 | < 0.001 |
| Diabetes, N(%) | 95 (40.6%) | 36 (45.6%) | 28 (36.4%) | 31 (39.7%) | 0.50 |
| Lead Position (LAO) | |||||
| Anterior/ Anterolateral/ Anteroseptal, N (%) | 66 (29.1%) | 26 (33.3%) | 16 (21.3%) | 24 (32.4%) | 0.19 |
| Posterior/ Posterolateral, N (%) | 161 (70.9%) | 52 (66.7%) | 59 (78.7%) | 50 (67.6%) | |
| Lead Position (RAO) | |||||
| Apical, N (%) | 25 (11.0%) | 5 (6.4%) | 8 (10.7%) | 12 (16.2%) | 0.061 |
| Basal, N (%) | 9 (4.0%) | 2 (2.6%) | 1 (1.3%) | 6 (8.1%) | |
| Mid, N (%) | 193 (85.0%) | 71 (91.0%) | 66 (88.0%) | 56 (75.7%) | |